Matthijs Westerman

2.0k total citations
16 papers, 158 citations indexed

About

Matthijs Westerman is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Matthijs Westerman has authored 16 papers receiving a total of 158 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 8 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Matthijs Westerman's work include Multiple Myeloma Research and Treatments (9 papers), Cancer Treatment and Pharmacology (4 papers) and Influenza Virus Research Studies (3 papers). Matthijs Westerman is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Cancer Treatment and Pharmacology (4 papers) and Influenza Virus Research Studies (3 papers). Matthijs Westerman collaborates with scholars based in Netherlands, United States and France. Matthijs Westerman's co-authors include A. Meerveld-Eggink, Annette W.G. van der Velden, Ger T. Rijkers, Ankie M.T. van der Velden, Douwe H. Biesma, Marten R. Nijziel, Aart Beeker, Maartje Los, Jacqueline M. Stouthard and Okke de Weerdt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Matthijs Westerman

15 papers receiving 157 citations

Peers

Countries citing papers authored by Matthijs Westerman

Since Specialization

Citations

This map shows the geographic impact of Matthijs Westerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthijs Westerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthijs Westerman more than expected).

Fields of papers citing papers by Matthijs Westerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthijs Westerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthijs Westerman. The network helps show where Matthijs Westerman may publish in the future.

Co-authorship network of co-authors of Matthijs Westerman

This figure shows the co-authorship network connecting the top 25 collaborators of Matthijs Westerman. A scholar is included among the top collaborators of Matthijs Westerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthijs Westerman. Matthijs Westerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes 2024 ·HemaSphere ·(unknown), (unknown), Kazem Nasserinejad, Mark‐David Levin, Josien C. Regelink, (unknown), (unknown), Matthijs Westerman, Gerjo A. Velders, Koen de Heer, (unknown), Roel J.W. van Kampen, Claudia A.M. Stege, (unknown), Inger S. Nijhof, Ellen van der Spek, Saskia K. Klein, Niels W.C.J. van de Donk, Paula F. Ypma, Sonja Zweegman	5
2	Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma 2024 ·Blood ·(unknown), Kazem Nasserinejad, Mark‐David Levin, (unknown), (unknown), Josien C. Regelink, Gerjo A. Velders, Matthijs Westerman, (unknown), (unknown), (unknown), Claudia A.M. Stege, (unknown), (unknown), Monique C. Minnema, Pieter Sonneveld, Paula F. Ypma, Niels W.C.J. van de Donk, Sonja Zweegman	0
3	Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd) 2024 ·Blood ·(unknown), Wouter J. Plattel, Elizabeth de Kort, Alexandra Croockewit, Mark‐David Levin, Matthijs Westerman, Okke de Weerdt, Inger S. Nijhof, Jurgen Wegman, Nico P.M. Smit, Christie P.M. Verkleij, Tuna Mutis, Marjolein van der Klift, (unknown), (unknown), Ellen van der Spek, Wilfried Roeloffzen, Sonja Zweegman, Niels W.C.J. van de Donk	1
4	Two-sided femoral Campylobacter jejuni osteomyelitis in a patient with acquired hypogammaglobulinemia: a case report 2020 ·BMC Infectious Diseases ·(unknown), Matthijs Westerman, Jiri F. P. Wagenaar	5
5	Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study. 2019 ·Journal of Clinical Oncology ·Cyrille Hulin, Philippe Moreau, Michel Attal, Karim Belhadj, Lotfi Benboubker, Denis Caillot, Thierry Façon, Laurent Garderet, Frédérique Kuhnowski, Anne‐Marie Stoppa, Brigitte Kolb, Mourad Tiab, Pieter Sonneveld, Kon‐Siong G. Jie, Matthijs Westerman, Lixia Pei, Tobias Kampfenkel, Carla de Boer, Jessica Vermeulen, Niels W.C.J. van de Donk, (unknown)	3
6	PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D‐VTD): PHASE 3 CASSIOPEIA STUDY 2019 ·HemaSphere ·Cyrille Hulin, Philippe Moreau, Michel Attal, Karim Belhadj, Lotfi Benboubker, Denis Caillot, Thierry Façon, Laurent Garderet, (unknown), A. M. Stoppa, Brigitte Kolb, Mourad Tiab, Pieter Sonneveld, (unknown), Matthijs Westerman, Lixia Pei, Tobias Kampfenkel, Carla de Boer, Jessica Vermeulen, (unknown)	4
7	Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Pieter Sonneveld, Michel Attal, Aurore Perrot, Cyrille Hulin, Denis Caillot, Thierry Façon, Xavier Leleu, (unknown), Lionel Karlin, Lofti Benboubker, Mark‐David Levin, Monique C. Minnema, Matthijs Westerman, Michel Delforge, Sonja Zweegman, Lixia Pei, Carla de Boer, Véronique Vanquickelberghe, Tobias Kampfenkel, Philippe Moreau	9
8	Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study 2018 ·Blood ·Claudia A.M. Stege, Kazem Nasserinejad, Mark‐David Levin, Saskia K. Klein, (unknown), Corien Eeltink, (unknown), Paula F. Ypma, (unknown), Matthijs Westerman, Wendy Deenik, Bea C. Tanis, Monique C. Minnema, Henk M.W. Verheul, Birgit I. Lissenberg‐Witte, (unknown), Pieter Sonneveld, Sonja Zweegman	12
9	Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study 2018 ·Blood ·Claudia A.M. Stege, Kazem Nasserinejad, Mark‐David Levin, Noortje Thielen, Saskia K. Klein, Inge Ludwig, Matthijs Westerman, Paula F. Ypma, Yavuz M. Bilgin, Maaike Söhne, (unknown), (unknown), Pieter Sonneveld, Sonja Zweegman	13
10	Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study 2016 ·Blood ·Sonja Zweegman, Mark‐David Levin, Saskia K. Klein, (unknown), Corien Eeltink, Paula F. Ypma, (unknown), Matthijs Westerman, Wendy Deenik, Bea C. Tanis, Monique S. Slee-Valentijn, Monique C. Minnema, Heleen Visser-Wisselaar, Claudia A.M. Stege, Niels W.C.J. van de Donk, Kazem Nasserinejad, Pieter Sonneveld	4
11	Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study 2016 ·Bone Marrow Transplantation ·Michel van Gelder, M. H. van Oers, Wendimagegn Alemayehu, (unknown), Jan J. Cornelissen, Martine E.D. Chamuleau, Pierre Zachée, Mels Hoogendoorn, Marcel Nijland, Eefke Petersen, Aart Beeker, G.J. Timmers, Leo F. Verdonck, Matthijs Westerman, Okke de Weerdt, Arnon P. Kater	7
12	1960 The perceptions of women with breast cancer during treatment with chemotherapy on changes in weight; a mixed methods approach 2015 ·European Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), Y. de Vries, (unknown), (unknown), Mintsje de Boer, Marjolein Visser, Ellen Kampman, Matthijs Westerman	1
13	Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours 2013 ·Vaccine ·M.L. Wumkes, Ankie M.T. van der Velden, Maartje Los, Mark Leys, Aart Beeker, Marten R. Nijziel, Annette W.G. van der Velden, Matthijs Westerman, A. Meerveld-Eggink, G.F. Rimmelzwaan, Ger T. Rijkers, Douwe H. Biesma	36
14	Influenza vaccination coverage in patients treated with chemotherapy: current clinical practice. 2013 ·PubMed ·M.L. Wumkes, Ankie M.T. van der Velden, Annette W.G. van der Velden, Jacqueline M. Stouthard, Marten R. Nijziel, Matthijs Westerman, Aart Beeker, A. Meerveld-Eggink, Ger T. Rijkers, Douwe H. Biesma	12
15	Response to influenza virus vaccination during chemotherapy in patients with breast cancer 2011 ·Annals of Oncology ·A. Meerveld-Eggink, Okke de Weerdt, Ankie M.T. van der Velden, Maartje Los, Annette W.G. van der Velden, Jacqueline M. Stouthard, Marten R. Nijziel, Matthijs Westerman, Aart Beeker, Ruud van Beek, Guus F. Rimmelzwaan, Ger T. Rijkers, Douwe H. Biesma	45
16	Grossesse chez une patiente présentant un syndrome de SAPHO 2006 ·Gynécologie Obstétrique & Fertilité ·(unknown), Aurélie Revaux, (unknown), Matthijs Westerman, J C Colau	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact